Investment
Features
FeesSafety
Academy
More
Pluang+

LightPath Technologies posts 109% revenue growth and positive EBITDA, driven by defense demand and capacity expansion.

Analyst Insights
11 May 2026
Seeking Alpha
View Source
Bullish
pluang ai news

LightPath Technologies has transformed into a vertically integrated infrared optics and imaging systems provider, reporting a 109% year-over-year revenue increase to $19.1 million in Q3 and a 700 basis point gross margin expansion to 36%. The company achieved positive adjusted EBITDA for the third consecutive quarter, supported by a record $110 million backlog and the acquisition of Amorphous Materials, which doubles its glass capacity. This positions LightPath to benefit from U.S. defense supply chain mandates, especially as it replaces China-sourced germanium with BlackDiamond. The company aims for over $300 million in annual revenue, with a buy rating and a $17 price target reflecting 50% upside potential.

More News

Health plan cuts machine-readable file production from 45 days to under 24 hours with TALON integration

Health plan cuts machine-readable file production from 45 days to under 24 hours with TALON integration

A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...

Others
Neutral
50 minutes ago
ASUS launches new durable Chromebooks CM15 and CM32 with long battery life and Google AI features in the US

ASUS launches new durable Chromebooks CM15 and CM32 with long battery life and Google AI features in the US

ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...

Others
Bullish
1 hour ago
Slate Medicines appoints Mark W. Hahn to board to boost migraine drug development.

Slate Medicines appoints Mark W. Hahn to board to boost migraine drug development.

Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...

Company Fundamentals
Bullish
2 hours ago
Global clinical trials market to reach $176.32B by 2030, driven by AI and decentralized research advances

Global clinical trials market to reach $176.32B by 2030, driven by AI and decentralized research advances

The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...

Market News
Bullish
4 hours ago
Hybrid robots market to hit $10B by 2030 driven by AI, smart manufacturing, and North America leadership

Hybrid robots market to hit $10B by 2030 driven by AI, smart manufacturing, and North America leadership

The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App